Please cite this article in press Rushikesh R Sakpelliwar et al, Questionary Based Awareness For Insulin Product By Community Pharmacist In Amravati District, Indo Am. J. P. Sci, 2023; 10 (09).

1. M. S. Rahman et al., “Role of insulin in health and disease: An update,” Int. J. Mol. Sci., vol. 22, no. 12, pp. 1–19, 2021, doi: 10.3390/ijms22126403.
2. R. Khursheed et al., “Treatment strategies against diabetes: Success so far and challenges ahead.,” Eur. J. Pharmacol., vol. 862, p. 172625, Nov. 2019, doi: 10.1016/j.ejphar.2019.172625.
3. A. Chaudhury et al., “Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management.,” Front. Endocrinol. (Lausanne)., vol. 8, p. 6, 2017, doi: 10.3389/fendo.2017.00006.
4. V. R. A/L B Vasanth Rao, S. H. Tan, M. Candasamy, and S. K. Bhattamisra, “Diabetic nephropathy: An update on pathogenesis and drug development.,” Diabetes Metab. Syndr., vol. 13, no. 1, pp. 754–762, 2019, doi: 10.1016/j.dsx.2018.11.054.
5. K. Papatheodorou, M. Banach, M. Edmonds, N. Papanas, and D. Papazoglou, “Complications of Diabetes.,” Journal of diabetes research, vol. 2015. England, p. 189525, 2015. doi: 10.1155/2015/189525.
6. S. Kalra et al., “Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus – International Task Force.,” Indian J. Endocrinol. Metab., vol. 22, no. 1, pp. 132–157, 2018, doi: 10.4103/ijem.IJEM_556_17.
7. S. Padhi, A. K. Nayak, and A. Behera, “Type II diabetes mellitus: a review on recent drug based therapeutics.,” Biomed. Pharmacother., vol. 131, p. 110708, Nov. 2020, doi: 10.1016/j.biopha.2020.110708.
8. C. Matos, F. van Hunsel, R. Tavares Ribeiro, D. Nascimento do Ó, and J. F. Raposo, “Diabetes patient’s pharmacovigilance knowledge and risk perception: the influence of being part of a patient organisation.,” Ther. Adv. drug Saf., vol. 11, p. 2042098620953935, 2020, doi: 10.1177/2042098620953935.
9. G. Durrieu, C. Hurault, V. Bongard, C. Damase-Michel, and J. L. Montastruc, “Perception of risk of adverse drug reactions by medical students: influence of a 1 year pharmacological course.,” Br. J. Clin. Pharmacol., vol. 64, no. 2, pp. 233–236, Aug. 2007, doi: 10.1111/j.1365-2125.2007.02882.x.
10. P. Comtex, N. Network, and N. Biod, “Biodel Inc . Announces VIAject ( TM ) Data at Oral Presentation at the American Diabetes Association Meeting,” 2007.
11. Z. Fu, E. R. Gilbert, and D. Liu, “Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes.,” Curr. Diabetes Rev., vol. 9, no. 1, pp. 25–53, Jan. 2013.
12. J. Boucher, A. Kleinridders, and C. R. Kahn, “Insulin receptor signaling in normal and insulin-resistant states.,” Cold Spring Harb. Perspect. Biol., vol. 6, no. 1, Jan. 2014, doi: 10.1101/cshperspect.a009191.
13. X. Huang, G. Liu, J. Guo, and Z. Su, “The PI3K/AKT pathway in obesity and type 2 diabetes.,” Int. J. Biol. Sci., vol. 14, no. 11, pp. 1483–1496, 2018, doi: 10.7150/ijbs.27173.
14. P. Wee and Z. Wang, “Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways.,” Cancers (Basel)., vol. 9, no. 5, May 2017, doi: 10.3390/cancers9050052.
15. D. Schröder and H. Zühlke, “Gene technology, characterization of insulin gene and the relationship to diabetes research.,” Endokrinologie, vol. 79, no. 2, pp. 197–209, Jun. 1982.
16. W. T. Cefalu, “Insulin resistance: cellular and clinical concepts.,” Exp. Biol. Med. (Maywood)., vol. 226, no. 1, pp. 13–26, Jan. 2001, doi: 10.1177/153537020122600103.
17. F. Kulozik and C. Hasslacher, “Insulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin?,” Ther. Adv. Endocrinol. Metab., vol. 4, no. 4, pp. 113–121, Aug. 2013, doi: 10.1177/2042018813501188.
18. H. Of et al., “INDICATIONS AND USAGE HUMULIN R U-500 is a concentrated human insulin indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus requiring more than 200 units of insulin per day.
19. Rubino, L. J. McQuay, S. C. Gough, M. Kvasz, and P. Tennis, “Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with Type 2 diabetes: a population-based analysis in the UK.,” Diabet. Med., vol. 24, no. 12, pp. 1412–1418, Dec. 2007, doi: 10.1111/j.1464-5491.2007.02279.x.
20. G. A. Nichols, Y. H. Koo, and S. N. Shah, “Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy.,” J. Gen. Intern. Med., vol. 22, no. 4, pp. 453–458, Apr. 2007, doi: 10.1007/s11606-007-0139-y.
21. H. Yki-Järvinen et al., “Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus.,” J. Clin. Endocrinol. Metab., vol. 82, no. 12, pp. 4037–4043, Dec. 1997, doi: 10.1210/jcem.82.12.4460.
22. M. J. Alomar, “Factors affecting the development of adverse drug reactions (Review article).,” Saudi Pharm. J. SPJ Off. Publ. Saudi Pharm. Soc., vol. 22, no. 2, pp. 83–94, Apr. 2014, doi: 10.1016/j.jsps.2013.02.003.
23. A. Barnett, A. Begg, P. Dyson, M. Feher, S. Hamilton, and N. Munro, “Insulin for type 2 diabetes: choosing a second-line insulin regimen.,” Int. J. Clin. Pract., vol. 62, no. 11, pp. 1647–1653, Nov. 2008, doi: 10.1111/j.1742-1241.2008.01909.x.
24. J. Rosenstock, M. Davies, P. D. Home, J. Larsen, C. Koenen, and G. Schernthaner, “A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.,” Diabetologia, vol. 51, no. 3, pp. 408–416, Mar. 2008, doi: 10.1007/s00125-007-0911-x.
25. R. G. Bretzel, U. Nuber, W. Landgraf, D. R. Owens, C. Bradley, and T. Linn, “Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.,” Lancet (London, England), vol. 371, no. 9618, pp. 1073–1084, Mar. 2008, doi: 10.1016/S0140-6736(08)60485-7.
26. L. Monnier, H. Lapinski, and C. Colette, “Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).,” Diabetes Care, vol. 26, no. 3, pp. 881–885, Mar. 2003, doi: 10.2337/diacare.26.3.881.
27. R. R. Holman et al., “Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.,” N. Engl. J. Med., vol. 357, no. 17, pp. 1716–1730, Oct. 2007, doi: 10.1056/NEJMoa075392.
28. M. J. Calvert, R. J. McManus, and N. Freemantle, “Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study.,” Br. J. Gen. Pract. J. R. Coll. Gen. Pract., vol. 57, no. 539, pp. 455–460, Jun. 2007.
29. O. Gawa, :“»„¸o„˝ß `I„‰ 1 ¡¡ » ( 1,” vol. 17. 2007.
30. “1. Promoting Health and Reducing Disparities in Populations.,” Diabetes Care, vol. 40, no. Suppl 1, pp. S6–S10, Jan. 2017, doi: 10.2337/dc17-S004.